Myung Eun Jung

USPTO Granted Patents = 10 (Patent Applications = 1)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 12.6

ph-index = 2

Forward Citations = 40(Granted Patents)

Location History:

Seongnam-si, KR (2011)
Yongin-si, KR (2012 - 2016)
Yongin, KR (2017)

Company Filing History:

9 out of 260

The Green Cross Corporation

patents

1 out of 6

Cmg Pharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2011-2017

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9701681 - Fused ring heteroaryl compounds and their use as Trk inhibitors (2017-07-11),

2. 9371303 - Diphenylmethane derivatives as SGLT2 inhibitors (2016-06-21),

3. 9340521 - Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives (2016-05-17),

4. 9034921 - Diphenylmethane derivatives as SGLT2 inhibitors (2015-05-19),

5. 8835436 - Arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same (2014-09-16),

6. 8785453 - Arylpiperazine-containing purine derivatives and uses thereof (2014-07-22),

7. 8541380 - C-aryl glucoside SGLT2 inhibitors and pharmaceutical compositions comprising same (2013-09-24),

8. 8309584 - Sulfur containing pyrazole-heterocycle derivatives as cannabinoid CB1 receptor antagonists (2012-11-13),

9. 8178551 - Orally bioavailable prodrugs of (+)-3-hydroxymorphinan for Parkinson'S disease prevention or treatment (2012-05-15),

10. 7875647 - Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists (2011-01-25),

Title: Myung Eun Jung: Innovator in Pharmaceutical Chemistry

Introduction

Myung Eun Jung is a prominent inventor based in Seongnam-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, holding a total of 10 patents. His work focuses on developing novel compounds that have the potential to treat various medical conditions.

Latest Patents

Among his latest patents, Myung Eun Jung has developed fused ring heteroaryl compounds that serve as Trk inhibitors. These compounds are represented by a specific formula and can be utilized in treating pain, cancer, inflammation, neurodegenerative diseases, and certain infectious diseases. Additionally, he has patented diphenylmethane derivatives that act as SGLT2 inhibitors. These compounds are particularly useful in preventing or treating metabolic disorders, especially diabetes.

Career Highlights

Myung Eun Jung has worked with notable companies in the pharmaceutical industry, including the Green Cross Corporation and Cmg Pharmaceutical Co., Ltd. His innovative research and development efforts have led to advancements in drug formulations and therapeutic applications.

Collaborations

Throughout his career, Myung Eun Jung has collaborated with esteemed colleagues such as Suk Ho Lee and Hee Jeong Seo. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in pharmaceutical chemistry.

Conclusion

Myung Eun Jung's contributions to the field of pharmaceutical chemistry are noteworthy, with a focus on developing innovative compounds for treating various diseases. His work continues to impact the medical community positively.

This text is generated by artificial intelligence and may not be accurate.